Literature DB >> 23001410

Post-transplantation B cell function in different molecular types of SCID.

Rebecca H Buckley1, Chan M Win, Barry K Moser, Roberta E Parrott, Elisa Sajaroff, Marcella Sarzotti-Kelsoe.   

Abstract

PURPOSE: Severe combined immunodeficiency (SCID) is a syndrome of diverse genetic cause characterized by profound deficiencies of T, B and sometimes NK cell function. Non-ablative HLA-identical or rigorously T cell-depleted haploidentical parental bone marrow transplantation (BMT) results in thymus-dependent genetically donor T cell development in the recipients, leading to a high rate of long-term survival. However, the development of B cell function has been more problematic. We report here results of analyses of B cell function in 125 SCID recipients prior to and long-term after non-ablative BMT, according to their molecular type.
METHODS: Studies included blood immunoglobulin measurements; antibody titers to standard vaccines, blood group antigens and bacteriophage Φ X 174; flow cytometry to examine for markers of immaturity, memory, switched memory B cells and BAFF receptor expression; B cell chimerism; B cell spectratyping; and B cell proliferation.
RESULTS: The results showed that B cell chimerism was not required for normal B cell function in IL7Rα-Def, ADA-Def and CD3-Def SCIDs. In X-linked-SCID, Jak3-Def SCID and those with V-D-J recombination defects, donor B cell chimerism was necessary for B cell function to develop.
CONCLUSION: The most important factor determining whether B cell function develops in SCID T cell chimeras is the underlying molecular defect. In some types, host B cells function normally. In those molecular types where host B cell function did not develop, donor B cell chimerism was necessary to achieve B cell function. 236 words.

Entities:  

Mesh:

Year:  2012        PMID: 23001410      PMCID: PMC3549311          DOI: 10.1007/s10875-012-9797-6

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  52 in total

1.  Use of family specific leader region primers for PCR amplification of the human heavy chain variable region gene repertoire.

Authors:  M J Campbell; A D Zelenetz; S Levy; R Levy
Journal:  Mol Immunol       Date:  1992-02       Impact factor: 4.407

2.  Detection of Y chromosome by in situ hybridization in combination with membrane antigens by two-color immunofluorescence.

Authors:  H van den Berg; J M Vossen; R Langlois van den Bergh; J Bayer; M J van Tol
Journal:  Lab Invest       Date:  1991-05       Impact factor: 5.662

3.  Interleukin-4 signaling in B lymphocytes from patients with X-linked severe combined immunodeficiency.

Authors:  N Taylor; F Candotti; S Smith; S A Oakes; T Jahn; J Isakov; J M Puck; J J O'Shea; K Weinberg; J A Johnston
Journal:  J Biol Chem       Date:  1997-03-14       Impact factor: 5.157

Review 4.  Immune regulation by CD40 and its ligand GP39.

Authors:  T M Foy; A Aruffo; J Bajorath; J E Buhlmann; R J Noelle
Journal:  Annu Rev Immunol       Date:  1996       Impact factor: 28.527

5.  Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency.

Authors:  R H Buckley; S E Schiff; R I Schiff; L Markert; L W Williams; J L Roberts; L A Myers; F E Ward
Journal:  N Engl J Med       Date:  1999-02-18       Impact factor: 91.245

6.  Long-term chimerism and B-cell function after bone marrow transplantation in patients with severe combined immunodeficiency with B cells: A single-center study of 22 patients.

Authors:  E Haddad; F Le Deist; P Aucouturier; M Cavazzana-Calvo; S Blanche; G De Saint Basile; A Fischer
Journal:  Blood       Date:  1999-10-15       Impact factor: 22.113

7.  Immunologic reconstitution after haploidentical bone marrow transplantation for immune deficiency disorders: treatment of bone marrow cells with monoclonal antibody CT-2 and complement.

Authors:  R C Moen; S D Horowitz; P M Sondel; W R Borcherding; M E Trigg; R Billing; R Hong
Journal:  Blood       Date:  1987-09       Impact factor: 22.113

8.  Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency.

Authors:  A Puel; S F Ziegler; R H Buckley; W J Leonard
Journal:  Nat Genet       Date:  1998-12       Impact factor: 38.330

9.  Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans.

Authors:  M Noguchi; H Yi; H M Rosenblatt; A H Filipovich; S Adelstein; W S Modi; O W McBride; W J Leonard
Journal:  Cell       Date:  1993-04-09       Impact factor: 41.582

10.  Severe combined immunodeficiency caused by deficiency in either the delta or the epsilon subunit of CD3.

Authors:  Geneviève de Saint Basile; Frédéric Geissmann; Elisabeth Flori; Béatrice Uring-Lambert; Claire Soudais; Marina Cavazzana-Calvo; Anne Durandy; Nada Jabado; Alain Fischer; Françoise Le Deist
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

View more
  30 in total

Review 1.  Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Stem Cell Transplantation (HCT) for Severe Combined Immunodeficiency Patients: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT.

Authors:  Jennifer Heimall; Jennifer Puck; Rebecca Buckley; Thomas A Fleisher; Andrew R Gennery; Benedicte Neven; Mary Slatter; Elie Haddad; Luigi D Notarangelo; K Scott Baker; Andrew C Dietz; Christine Duncan; Michael A Pulsipher; Mort J Cowan
Journal:  Biol Blood Marrow Transplant       Date:  2017-01-06       Impact factor: 5.742

2.  Hematopoietic Stem Cell Transplantation for Severe Combined Immunodeficiency.

Authors:  Justin T Wahlstrom; Christopher C Dvorak; Morton J Cowan
Journal:  Curr Pediatr Rep       Date:  2015-03-01

Review 3.  Long term outcomes of severe combined immunodeficiency: therapy implications.

Authors:  Jennifer Heimall; Morton J Cowan
Journal:  Expert Rev Clin Immunol       Date:  2017-09-23       Impact factor: 4.473

4.  Survey on retransplantation criteria for patients with severe combined immunodeficiency.

Authors:  Elie Haddad; Zoulfia Allakhverdi; Linda M Griffith; Morton J Cowan; Luigi D Notarangelo
Journal:  J Allergy Clin Immunol       Date:  2013-12-10       Impact factor: 10.793

Review 5.  Recommendations for Screening and Management of Late Effects in Patients with Severe Combined Immunodeficiency after Allogenic Hematopoietic Cell Transplantation: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT.

Authors:  Jennifer Heimall; Rebecca H Buckley; Jennifer Puck; Thomas A Fleisher; Andrew R Gennery; Elie Haddad; Benedicte Neven; Mary Slatter; Skinner Roderick; K Scott Baker; Andrew C Dietz; Christine Duncan; Linda M Griffith; Luigi Notarangelo; Michael A Pulsipher; Morton J Cowan
Journal:  Biol Blood Marrow Transplant       Date:  2017-05-04       Impact factor: 5.742

Review 6.  Hematopoietic stem cell transplantation for primary immunodeficiencies.

Authors:  Elizabeth Kang; Andrew Gennery
Journal:  Hematol Oncol Clin North Am       Date:  2014-09-16       Impact factor: 3.722

7.  Human lymphoid development in the absence of common γ-chain receptor signaling.

Authors:  Lisa A Kohn; Christopher S Seet; Jessica Scholes; Felicia Codrea; Rebecca Chan; Sania Zaidi-Merchant; Yuhua Zhu; Satiro De Oliveira; Neena Kapoor; Ami Shah; Hisham Abdel-Azim; Donald B Kohn; Gay M Crooks
Journal:  J Immunol       Date:  2014-04-25       Impact factor: 5.422

8.  B-cell differentiation and IL-21 response in IL2RG/JAK3 SCID patients after hematopoietic stem cell transplantation.

Authors:  Alexandra M Miggelbrink; Brent R Logan; Rebecca H Buckley; Roberta E Parrott; Christopher C Dvorak; Neena Kapoor; Hisham Abdel-Azim; Susan E Prockop; David Shyr; Hélène Decaluwe; Imelda C Hanson; Alfred Gillio; Blachy J Dávila Saldaña; Hermann Eibel; Gregory Hopkins; Jolan E Walter; Jennifer S Whangbo; Donald B Kohn; Jennifer M Puck; Morton J Cowan; Linda M Griffith; Elie Haddad; Richard J O'Reilly; Luigi D Notarangelo; Sung-Yun Pai
Journal:  Blood       Date:  2018-05-04       Impact factor: 22.113

9.  Unconditioned unrelated donor bone marrow transplantation for IL7Rα- and Artemis-deficient SCID.

Authors:  C C Dvorak; K Patel; J M Puck; J Wahlstrom; M J Dorsey; R Adams; J Facchino; M J Cowan
Journal:  Bone Marrow Transplant       Date:  2017-04-24       Impact factor: 5.483

10.  Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency.

Authors:  Maria Pia Cicalese; Francesca Ferrua; Laura Castagnaro; Roberta Pajno; Federica Barzaghi; Stefania Giannelli; Francesca Dionisio; Immacolata Brigida; Marco Bonopane; Miriam Casiraghi; Antonella Tabucchi; Filippo Carlucci; Eyal Grunebaum; Mehdi Adeli; Robbert G Bredius; Jennifer M Puck; Polina Stepensky; Ilhan Tezcan; Katie Rolfe; Erika De Boever; Rickey R Reinhardt; Jonathan Appleby; Fabio Ciceri; Maria Grazia Roncarolo; Alessandro Aiuti
Journal:  Blood       Date:  2016-04-29       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.